This study will determine the safety, tolerability and activity of CDX-527.~Eligible patients that enroll to the dose-escalation portion of the study will be assigned to one of several dose levels of CDX-527. The dose-escalation part of the study will determine the safety profile of CDX-527 and determine which dose(s) of CDX-527 will be studied in the expansion part of the study.~The expansion part of the study will enroll eligible patients with certain solid tumors to be treated at dose(s) identified during dose-escalation~Up to 40 patients will be enrolled. All patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.